Therapeutic targets of hypercholesterolemia: HMGCR and LDLR

Cholesterol homeostasis is critical and necessary for the body’s functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low–density lipoprotein cholesterol receptor (LDLR) are major...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shizhan, Sun, Wenxiu, Gao, Ling, Liu, Shudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709517/
https://www.ncbi.nlm.nih.gov/pubmed/31686875
http://dx.doi.org/10.2147/DMSO.S219013
Descripción
Sumario:Cholesterol homeostasis is critical and necessary for the body’s functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low–density lipoprotein cholesterol receptor (LDLR) are major points of control in cholesterol homeostasis. We summarize the regulatory mechanisms of HMGCR and LDLR, which may provide insight for new drug design and development.

Ejemplares similares